posted on 2022-05-11, 19:06authored bySamer
A. Naffouje, Masahide Goto, Lori U. Coward, Gregory S. Gorman, Konstantin Christov, Jing Wang, Albert Green, Anne Shilkaitis, Tapas K. Das Gupta, Tohru Yamada
Precise identification of the tumor
margins during breast-conserving
surgery (BCS) remains a challenge given the lack of visual discrepancy
between malignant and surrounding normal tissues. Therefore, we developed
a fluorescent imaging agent, ICG-p28, for intraoperative imaging guidance
to better aid surgeons in achieving negative margins in BCS. Here,
we determined the pharmacokinetics (PK), biodistribution, and preclinical
toxicity of ICG-p28. The PK and biodistribution of ICG-p28 indicated
rapid tissue uptake and localization at tumor lesions. There were
no dose-related effect and no significant toxicity in any of the breast
cancer and normal cell lines tested. Furthermore, ICG-p28 was evaluated
in clinically relevant settings with transgenic mice that spontaneously
developed invasive mammary tumors. Intraoperative imaging with ICG-p28
showed a significant reduction in the tumor recurrence rate. This
simple, nontoxic, and cost-effective method can offer a new approach
that enables surgeons to intraoperatively identify tumor margins and
potentially improves overall outcomes by reducing recurrence rates.